Biogen Inc (BIIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biogen Inc (BIIB) has a cash flow conversion efficiency ratio of 0.028x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($511.90 Million) by net assets ($18.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIIB days of operational coverage to measure how many days the company can operate on defensive assets alone.
Biogen Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Biogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pembina Pipeline Corp
TO:PPL
|
0.019x |
|
SHINHAN FINL ADR/1 SW5000
F:KSF1
|
-0.082x |
|
China National Nuclear Power
SHG:601985
|
0.057x |
|
Shenzhen Inovance Tech
SHE:300124
|
0.025x |
|
Arch Capital Group Ltd
F:RSK
|
0.049x |
|
NARI Technology Co Ltd
SHG:600406
|
0.034x |
|
CenterPoint Energy Inc
NYSE:CNP
|
0.025x |
|
Weichai Power Co Ltd Class A
SHE:000338
|
0.103x |
Annual Cash Flow Conversion Efficiency for Biogen Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Biogen Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see Biogen Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.26 Billion | $2.20 Billion | 0.121x | -29.80% |
| 2024-12-31 | $16.72 Billion | $2.88 Billion | 0.172x | +64.54% |
| 2023-12-31 | $14.80 Billion | $1.55 Billion | 0.105x | +1.11% |
| 2022-12-31 | $13.39 Billion | $1.38 Billion | 0.103x | -68.87% |
| 2021-12-31 | $10.96 Billion | $3.64 Billion | 0.332x | -16.09% |
| 2020-12-31 | $10.69 Billion | $4.23 Billion | 0.396x | -25.41% |
| 2019-12-31 | $13.34 Billion | $7.08 Billion | 0.531x | +11.76% |
| 2018-12-31 | $13.03 Billion | $6.19 Billion | 0.475x | +31.44% |
| 2017-12-31 | $12.60 Billion | $4.55 Billion | 0.361x | -3.12% |
| 2016-12-31 | $12.13 Billion | $4.52 Billion | 0.373x | -5.93% |
| 2015-12-31 | $9.37 Billion | $3.72 Billion | 0.396x | +45.70% |
| 2014-12-31 | $10.81 Billion | $2.94 Billion | 0.272x | +0.01% |
| 2013-12-31 | $8.62 Billion | $2.35 Billion | 0.272x | +0.77% |
| 2012-12-31 | $6.96 Billion | $1.88 Billion | 0.270x | +0.42% |
| 2011-12-31 | $6.43 Billion | $1.73 Billion | 0.269x | -9.83% |
| 2010-12-31 | $5.45 Billion | $1.62 Billion | 0.298x | +73.68% |
| 2009-12-31 | $6.26 Billion | $1.07 Billion | 0.172x | -36.30% |
| 2008-12-31 | $5.81 Billion | $1.56 Billion | 0.269x | +46.11% |
| 2007-12-31 | $5.53 Billion | $1.02 Billion | 0.184x | +56.74% |
| 2006-12-31 | $7.15 Billion | $841.27 Million | 0.118x | -8.65% |
| 2005-12-31 | $6.91 Billion | $889.50 Million | 0.129x | +20.78% |
| 2004-12-31 | $6.83 Billion | $727.99 Million | 0.107x | +243.13% |
| 2003-12-31 | $7.05 Billion | $219.21 Million | 0.031x | -81.43% |
| 2002-12-31 | $1.60 Billion | $267.08 Million | 0.167x | -28.63% |
| 2001-12-31 | $1.35 Billion | $316.36 Million | 0.235x | -29.09% |
| 2000-12-31 | $1.11 Billion | $365.94 Million | 0.331x | +18.98% |
| 1999-12-31 | $979.53 Million | $272.29 Million | 0.278x | +19.01% |
| 1998-12-31 | $718.61 Million | $167.84 Million | 0.234x | +28.30% |
| 1997-12-31 | $536.29 Million | $97.63 Million | 0.182x | +89.47% |
| 1996-12-31 | $484.37 Million | $46.54 Million | 0.096x | +289.43% |
| 1995-12-31 | $382.98 Million | $9.45 Million | 0.025x | -76.67% |
| 1994-12-31 | $329.93 Million | $34.89 Million | 0.106x | -27.76% |
| 1993-12-31 | $325.20 Million | $47.60 Million | 0.146x | -3.21% |
| 1992-12-31 | $285.00 Million | $43.10 Million | 0.151x | +512.60% |
| 1991-12-31 | $239.00 Million | $5.90 Million | 0.025x | -66.39% |
| 1990-12-31 | $145.70 Million | $10.70 Million | 0.073x | +236.30% |
| 1989-12-31 | $139.20 Million | $-7.50 Million | -0.054x | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more